The global IV flush syringe market size was estimated to be USD 389.42 million in 2023 and is expected to reach at USD 801.3 million by 2033 with a CAGR of 6.78% during the forecast period 2023-2033. Rising prevalence of chronic disorders, growing awareness regarding the benefits of using an IV Flush Syringe, increasing demand for flushing IV lines using IV flush syringes, surge in adoption of prefilled syringes by healthcare professionals, rising focus on the development of advanced products, growing technological advancements, and increasing investment by major market players are some of the key factors boosting the market growth.
Increasing investment by major market players is predicted to boost the market growth during the forecast period. For instance, in December 2020, Becton, Dickinson, and Company (BD) revealed its intention to invest approximately $1.2 million over a span of four years. This funding is aimed at enhancing manufacturing capabilities and technological advancements for pre-filled syringes.
By Product, Saline IV flush syringe was the highest revenue-grossing segment in the global IV flush syringe market in 2022 owing to the growing number of inpatient stays necessitate flushing due to the administration of several drugs for chronic diseases including chemotherapy (cancer), increasing introduction of innovative products, and rising initiatives by major market players. For instance, in May 2023, BD (Becton, Dickinson and Company) has unveiled broader access for customers to PosiFlush SafeScrub, an integrated disinfection unit combined with a prefilled saline flush syringe. This innovative solution is created to enhance adherence to infection prevention protocols and streamline nursing processes. Additionally, Heparin IV flush syringe is predicted to grow at fastest CAGR during the forecast period owing to the surge in usage of heparin flush syringes for patients undergoing angioplasty & heart valve surgery, rising demand for heparin flush to prevent blood clots & other complications related to medication administration.
By End-user, Hospitals & clinics was the highest revenue-grossing segment in the global IV flush syringe market in 2022 owing to the growing prevalence of chronic & acute diseases, surge in number of hospital admissions, rising demand for IV flush syringes for medication administration & tests, and increasing initiatives by key market players. For instance, in October 2021, The U.S. government now has easier access to safety injection devices because to BD (Becton, Dickinson, and Company), which has increased its manufacturing capacity. The creation of new syringe and needle manufacturing lines resulted from a collaboration between BD and the Department of Health and Human Services' (HHS) Assistant Secretary for Preparedness and Response (ASPR), which operates as a public-private partnership. Additionally, Ambulatory surgical centres is predicted to grow at fastest CAGR during the forecast period owing to the increasing usage of flush syringes, rising healthcare infrastructure, and growing technological advancements.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of chronic diseases, surge in number of surgical procedures performed, growing research and development activities, increasing adoption of novel technologies, and rising introduction of advanced products. For instance, in July 2021, Medline Industries, LP received recognition from the American weekly magazine Newsweek for its inclusion in the 'Best Infection Prevention Products 2021' list. The two products acknowledged are the 'Prefilled SwabFlush syringe with SwabCap' and 'ReadyPrep CHG'. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of chronic disorders, growing demand for prefilled syringes by healthcare professionals, rising technological advancements, and surge in approvals by regulatory bodies. For instance, in February 2022, A division of Owen Mumford called Owen Mumford Pharmaceutical Services has announced that the Asian market has approved their UniSafe 1 mL safety device for pre-filled syringes as a combination product.
Increasing investment by major market players is predicted to boost the market growth during the forecast period. For instance, in December 2020, Becton, Dickinson, and Company (BD) revealed its intention to invest approximately $1.2 million over a span of four years. This funding is aimed at enhancing manufacturing capabilities and technological advancements for pre-filled syringes.
By Product, Saline IV flush syringe was the highest revenue-grossing segment in the global IV flush syringe market in 2022 owing to the growing number of inpatient stays necessitate flushing due to the administration of several drugs for chronic diseases including chemotherapy (cancer), increasing introduction of innovative products, and rising initiatives by major market players. For instance, in May 2023, BD (Becton, Dickinson and Company) has unveiled broader access for customers to PosiFlush SafeScrub, an integrated disinfection unit combined with a prefilled saline flush syringe. This innovative solution is created to enhance adherence to infection prevention protocols and streamline nursing processes. Additionally, Heparin IV flush syringe is predicted to grow at fastest CAGR during the forecast period owing to the surge in usage of heparin flush syringes for patients undergoing angioplasty & heart valve surgery, rising demand for heparin flush to prevent blood clots & other complications related to medication administration.
By End-user, Hospitals & clinics was the highest revenue-grossing segment in the global IV flush syringe market in 2022 owing to the growing prevalence of chronic & acute diseases, surge in number of hospital admissions, rising demand for IV flush syringes for medication administration & tests, and increasing initiatives by key market players. For instance, in October 2021, The U.S. government now has easier access to safety injection devices because to BD (Becton, Dickinson, and Company), which has increased its manufacturing capacity. The creation of new syringe and needle manufacturing lines resulted from a collaboration between BD and the Department of Health and Human Services' (HHS) Assistant Secretary for Preparedness and Response (ASPR), which operates as a public-private partnership. Additionally, Ambulatory surgical centres is predicted to grow at fastest CAGR during the forecast period owing to the increasing usage of flush syringes, rising healthcare infrastructure, and growing technological advancements.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of chronic diseases, surge in number of surgical procedures performed, growing research and development activities, increasing adoption of novel technologies, and rising introduction of advanced products. For instance, in July 2021, Medline Industries, LP received recognition from the American weekly magazine Newsweek for its inclusion in the 'Best Infection Prevention Products 2021' list. The two products acknowledged are the 'Prefilled SwabFlush syringe with SwabCap' and 'ReadyPrep CHG'. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of chronic disorders, growing demand for prefilled syringes by healthcare professionals, rising technological advancements, and surge in approvals by regulatory bodies. For instance, in February 2022, A division of Owen Mumford called Owen Mumford Pharmaceutical Services has announced that the Asian market has approved their UniSafe 1 mL safety device for pre-filled syringes as a combination product.
Segmentation: IV Flush Syringe Market Report 2022 - 2033
IV Flush Syringe Market Analysis & Forecast by Product 2022 - 2033 (Revenue USD Mn)
- Heparin IV Flush Syringe
- Saline IV Flush Syringe
IV Flush Syringe Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Mn)
- Hospitals & Clinics
- Ambulatory Surgical Centres
- Others
IV Flush Syringe Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Mn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. IV Flush Syringe Market: Product Estimates & Trend Analysis
8. IV Flush Syringe Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America IV Flush Syringe Market
11. Europe Global IV Flush Syringe Market
12. Asia Pacific Global IV Flush Syringe Market
13. Latin America Global IV Flush Syringe Market
14. MEA Global IV Flush Syringe Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Cardinal Health
- BD (Becton
- Dickinson and Company)
- Medline Industries
- LP
- B. Braun Melsungen AG
- Nipro Corporation
- SteriCare Solutions
- Medefil Inc.
- Polymedicure
- Aquabiliti
- Owen Mumford Pharmaceutical
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 389.42 Million |
| Forecasted Market Value ( USD | $ 801.3 Million |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
